CO2022016810A2 - Método para tratamiento del cáncer cervicouterino - Google Patents
Método para tratamiento del cáncer cervicouterinoInfo
- Publication number
- CO2022016810A2 CO2022016810A2 CONC2022/0016810A CO2022016810A CO2022016810A2 CO 2022016810 A2 CO2022016810 A2 CO 2022016810A2 CO 2022016810 A CO2022016810 A CO 2022016810A CO 2022016810 A2 CO2022016810 A2 CO 2022016810A2
- Authority
- CO
- Colombia
- Prior art keywords
- cervical cancer
- treatment method
- cancer treatment
- hpv
- human papillomavirus
- Prior art date
Links
- 206010008342 Cervix carcinoma Diseases 0.000 title abstract 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 title abstract 2
- 201000010881 cervical cancer Diseases 0.000 title abstract 2
- 241000701806 Human papillomavirus Species 0.000 abstract 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Communicable Diseases (AREA)
Abstract
Se describe un tratamiento del cáncer de cuello uterino causado por la infección por el virus del papiloma humano (HPV). Se describen composiciones farmacéuticas que comprenden una vacuna contra el virus del papiloma humano (HPV) y un agente inhibidor de puntos de control para prevenir o tratar un cáncer inducido por el virus del papiloma humano (HPV).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063015076P | 2020-04-24 | 2020-04-24 | |
PCT/KR2021/005237 WO2021215896A1 (en) | 2020-04-24 | 2021-04-26 | Method for treating cervical cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022016810A2 true CO2022016810A2 (es) | 2023-02-27 |
Family
ID=78221098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0016810A CO2022016810A2 (es) | 2020-04-24 | 2022-11-23 | Método para tratamiento del cáncer cervicouterino |
Country Status (14)
Country | Link |
---|---|
US (1) | US11883479B2 (es) |
EP (1) | EP4138900A4 (es) |
JP (1) | JP7460094B2 (es) |
KR (2) | KR20220109444A (es) |
CN (1) | CN115551547A (es) |
AU (1) | AU2021261676A1 (es) |
BR (1) | BR112022021284A2 (es) |
CA (1) | CA3176240A1 (es) |
CO (1) | CO2022016810A2 (es) |
IL (1) | IL297502A (es) |
MX (1) | MX2022013063A (es) |
PE (1) | PE20231054A1 (es) |
WO (1) | WO2021215896A1 (es) |
ZA (1) | ZA202211410B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023172036A1 (ko) * | 2022-03-10 | 2023-09-14 | 주식회사 제넥신 | 두경부암 치료를 위한 삼중 복합약물 투여요법 |
WO2023196884A1 (en) | 2022-04-06 | 2023-10-12 | Juno Therapeutics, Inc. | Detection assay for human papillomavirus (hpv) type 16 (hpv-16) |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
AUPN015794A0 (en) | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
KR100201584B1 (ko) | 1996-07-12 | 1999-06-15 | 손경식 | 사람 파필로마 바이러스 18형 이6 단백질에 대한 인체의 면역성 조절 기능을 갖는 펩타이드 |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
JP2003509035A (ja) | 1999-09-16 | 2003-03-11 | ザイコス インク. | ポリエピトープポリペプチドをコードする核酸 |
ES2284559T3 (es) | 2001-03-23 | 2007-11-16 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Genes y proteinas e6 y e7 modificados del vph utiles como vacuna. |
KR100900249B1 (ko) | 2001-12-07 | 2009-05-29 | 포항공과대학교 산학협력단 | SIVmac239의 면역원성 플라스미드 및 이들을 함유한AIDS DNA 백신 |
KR101145190B1 (ko) | 2002-10-03 | 2012-05-14 | 와이어쓰 홀딩스 코포레이션 | 사람 파필로마바이러스 폴리펩타이드 및 면역원성 조성물 |
CN1299769C (zh) | 2005-01-31 | 2007-02-14 | 中国医学科学院肿瘤医院肿瘤研究所 | 人乳头瘤病毒和热休克蛋白重组蛋白疫苗及其用途 |
EP1757615B1 (en) | 2005-08-24 | 2011-08-24 | Healthbanks Biotech Co., Ltd. | Fusion protein for inhibiting cervical cancer |
US7732166B2 (en) | 2005-11-15 | 2010-06-08 | Oncohealth Corporation | Detection method for human pappilomavirus (HPV) and its application in cervical cancer |
US8137674B2 (en) | 2006-04-19 | 2012-03-20 | Postech Foundation | Compositions comprising HPV polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer |
WO2008046251A1 (fr) | 2006-10-19 | 2008-04-24 | Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. | Protéines hybrides contenant un domaine n de la calréticuline humaine et des protéines e6 ou e7 du papillomavirus humain de type 16, et utilisations associées |
DE102008010954A1 (de) | 2008-02-25 | 2009-08-27 | Cichon, Günter, Prof.Dr. | DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen |
EP2377879A1 (en) | 2010-04-14 | 2011-10-19 | Deutsches Krebsforschungszentrum | N-terminal HPV E7 fusion proteins |
CN103180343B (zh) | 2010-08-13 | 2016-01-20 | 株式会社吉耐森 | 用于预防或治疗宫颈癌的、包含人乳头瘤病毒变形体及免疫增强剂的组合物 |
DK2793937T3 (da) | 2011-12-21 | 2019-07-01 | Vaccibody As | Vacciner mod HPV |
EP3563836A1 (en) * | 2013-03-01 | 2019-11-06 | Astex Pharmaceuticals, Inc. | Drug combinations |
CN107073070A (zh) * | 2014-08-15 | 2017-08-18 | 格纳西尼有限公司 | 治疗宫颈癌的方法 |
CA3051252A1 (en) * | 2017-02-01 | 2018-08-09 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
US20180250378A1 (en) * | 2017-03-03 | 2018-09-06 | Papivax Biotech Inc. | Combination of therapeutic vaccine and pd-1-related blockade for treating human papillomavirus-associated diseases |
JP2020515542A (ja) * | 2017-03-23 | 2020-05-28 | ザ ジェネラル ホスピタル コーポレイション | Cxcr4/cxcr7の遮断およびヒトパピローマウイルス関連疾患の治療 |
-
2021
- 2021-04-26 PE PE2022002454A patent/PE20231054A1/es unknown
- 2021-04-26 IL IL297502A patent/IL297502A/en unknown
- 2021-04-26 US US17/240,224 patent/US11883479B2/en active Active
- 2021-04-26 MX MX2022013063A patent/MX2022013063A/es unknown
- 2021-04-26 EP EP21793447.0A patent/EP4138900A4/en active Pending
- 2021-04-26 WO PCT/KR2021/005237 patent/WO2021215896A1/en active Application Filing
- 2021-04-26 JP JP2022564262A patent/JP7460094B2/ja active Active
- 2021-04-26 AU AU2021261676A patent/AU2021261676A1/en active Pending
- 2021-04-26 BR BR112022021284A patent/BR112022021284A2/pt active Search and Examination
- 2021-04-26 KR KR1020227022552A patent/KR20220109444A/ko active Application Filing
- 2021-04-26 KR KR1020247005905A patent/KR20240029786A/ko active Application Filing
- 2021-04-26 CA CA3176240A patent/CA3176240A1/en active Pending
- 2021-04-26 CN CN202180030597.2A patent/CN115551547A/zh active Pending
-
2022
- 2022-10-18 ZA ZA2022/11410A patent/ZA202211410B/en unknown
- 2022-11-23 CO CONC2022/0016810A patent/CO2022016810A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN115551547A (zh) | 2022-12-30 |
PE20231054A1 (es) | 2023-07-11 |
JP7460094B2 (ja) | 2024-04-02 |
EP4138900A1 (en) | 2023-03-01 |
JP2023522989A (ja) | 2023-06-01 |
BR112022021284A2 (pt) | 2022-12-06 |
ZA202211410B (en) | 2024-02-28 |
EP4138900A4 (en) | 2024-05-15 |
MX2022013063A (es) | 2022-12-08 |
KR20220109444A (ko) | 2022-08-04 |
WO2021215896A1 (en) | 2021-10-28 |
AU2021261676A1 (en) | 2022-11-24 |
IL297502A (en) | 2022-12-01 |
US20210330779A1 (en) | 2021-10-28 |
CA3176240A1 (en) | 2021-10-28 |
KR20240029786A (ko) | 2024-03-06 |
US11883479B2 (en) | 2024-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2022016810A2 (es) | Método para tratamiento del cáncer cervicouterino | |
MX2023000314A (es) | Formulaciones farmaceuticas transdermicas de cannabinoides. | |
AR108829A1 (es) | Vacuna contra virus de bronquitis infecciosa | |
BR112022013646A2 (pt) | Método de tratamento de esplenomegalia | |
CO2023003242A2 (es) | Vacuna contra el coronavirus y procedimiento para la preparación de la misma | |
PE20220510A1 (es) | Inhibidores de la replicacion del virus de inmunodeficiencia humana | |
CO2022017989A2 (es) | Vacunas para la papilomatosis respiratoria recurrente y métodos para usar estas | |
CO2022002493A2 (es) | Nanoemulsion de ácido 18p-glicirretínico | |
CL2022003743A1 (es) | Formulaciones de tableta dispersable que comprenden dolutegravir | |
EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
CO2022015018A2 (es) | Métodos y medios para modificar la hemodinámica en infecciones | |
BR112022022379A2 (pt) | Bioinformática | |
Cerne et al. | A novel approach for treating nasal dog bite injury | |
MX2022012165A (es) | Interaccion de proteinas de sars-cov-2 con mecanismos moleculares y celulares de celulas huespedes y formulaciones para tratar covid-19. | |
WO2022129097A3 (en) | Sirna and compositions for prophylactic and therapeutic treatment of virus diseases | |
BR112022010733A2 (pt) | Métodos para tratar dor | |
PH12020550193A1 (en) | Photochemical preparation method for autologous plasma inactivated vaccine for treating aids | |
CO2022016537A2 (es) | Vacuna inactivada para sars-cov-2 y preparación de la misma | |
BR112022022845A2 (pt) | Tratamento de efeitos adversos causados por antipsicóticos atípicos | |
BR112021026839A2 (pt) | Composições farmacêuticas para tratar e para prevenir uma doença infecciosa do vírus influenza | |
BR112020015640A8 (pt) | Implante de malha autoexpansível para hernioplastia endoscópica | |
EA202190589A1 (ru) | Способ комбинированной терапии дисплазии шейки матки, ассоциированной с вирусами папилломы человека | |
RU2699661C1 (ru) | Способ лечения инфицированных ран у животных | |
BR112019012057A2 (pt) | agente antiviral, composição farmacêutica para a administração do mesmo e métodos de redução na replicação do vírus zika (zikv) e tratamento de doença mediada pelo vírus zika (zikv) | |
CL2023003323A1 (es) | Método para el tratamiento de la psoriasis |